GLSI Greenwich LifeSciences Inc

Price (delayed)

$15.605

Market cap

$200.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.72

Enterprise value

$195.49M

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a ...

Highlights
The quick ratio has plunged by 72% YoY and by 40% from the previous quarter
The equity has shrunk by 56% YoY and by 24% QoQ

Key stats

What are the main financial stats of GLSI
Market
Shares outstanding
12.88M
Market cap
$200.99M
Enterprise value
$195.49M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
39.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$9.24M
EBITDA
-$9.24M
Free cash flow
-$6.7M
Per share
EPS
-$0.72
Free cash flow per share
-$0.52
Book value per share
$0.4
Revenue per share
$0
TBVPS
$0.43
Balance sheet
Total assets
$5.51M
Total liabilities
$389,611
Debt
$0
Equity
$5.12M
Working capital
$5.12M
Liquidity
Debt to equity
0
Current ratio
14.14
Quick ratio
14.13
Net debt/EBITDA
0.6
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-113.4%
Return on equity
-118%
Return on invested capital
N/A
Return on capital employed
-180.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GLSI stock price

How has the Greenwich LifeSciences stock price performed over time
Intraday
-0.16%
1 week
-4.67%
1 month
5.72%
1 year
67.08%
YTD
48.34%
QTD
-9.59%

Financial performance

How have Greenwich LifeSciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.62M
Net income
-$9.24M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 16% year-on-year and by 3.2% since the previous quarter
The net income has contracted by 16% YoY and by 3.9% from the previous quarter

Growth

What is Greenwich LifeSciences's growth rate over time

Valuation

What is Greenwich LifeSciences stock price valuation
P/E
N/A
P/B
39.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GLSI's EPS is down by 14% year-on-year and by 4.3% since the previous quarter
GLSI's P/B is 65% higher than its last 4 quarters average of 23.7
The equity has shrunk by 56% YoY and by 24% QoQ

Efficiency

How efficient is Greenwich LifeSciences business performance
The return on equity has dropped by 112% year-on-year and by 26% since the previous quarter
The ROA has shrunk by 107% YoY and by 24% QoQ

Dividends

What is GLSI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLSI.

Financial health

How did Greenwich LifeSciences financials performed over time
The quick ratio has plunged by 72% YoY and by 40% from the previous quarter
The current ratio has plunged by 72% YoY and by 40% from the previous quarter
The company's debt is 100% lower than its equity
The equity has shrunk by 56% YoY and by 24% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.